Fidler I J
Department of Cell Biology, University of Texas System Cancer Center, M.D. Anderson and Tumor Institute, Houston 77030.
Isr J Med Sci. 1988 Sep-Oct;24(9-10):456-63.
The process of cancer metastasis is sequential and selective and contains stochastic elements. The growth of metastases represents the endpoint of many lethal events that few tumor cells can survive. Primary tumors consist of multiple subpopulations of cells with heterogeneous metastatic properties, cells whose successful metastasis depends on their interplay with various host factors. Cancer metastases can have a clonal origin, and different metastases can originate from different progenitor cells. Biologic diversity, however, is rapidly generated within metastases and, therefore, their eradication requires the use of multiple therapies early in the course of the disease, even when clear evidence of residual tumor is lacking. The design of specific antimetastatic therapies is dependent on a sound understanding of the biology of metastasis. The clinical challenge presented by neoplastic heterogeneity, especially as it affects metastasis and sensitivity to therapeutic agents, may appear insurmountable. However, it is important to remember that the process of metastasis is regulated by certain mechanisms that can be studied and hopefully understood. The recent increase in our understanding of the processes of tumor progression and metastasis should, therefore, provide important leads for developing more effective approaches for the treatment of disseminated cancer.
癌症转移过程是连续且具有选择性的,还包含随机因素。转移灶的生长代表了许多致命事件的终点,只有极少数肿瘤细胞能够存活下来。原发性肿瘤由具有异质性转移特性的多个细胞亚群组成,这些细胞的成功转移取决于它们与各种宿主因素的相互作用。癌症转移灶可能起源于克隆,不同的转移灶可能源自不同的祖细胞。然而,转移灶内会迅速产生生物学多样性,因此,即使在缺乏残留肿瘤明确证据的情况下,在疾病进程早期也需要使用多种疗法来根除它们。特异性抗转移疗法的设计依赖于对转移生物学的深入理解。肿瘤异质性带来的临床挑战,尤其是其对转移和治疗药物敏感性的影响,可能看似难以克服。然而,重要的是要记住,转移过程受某些机制调控,这些机制可以被研究并有望被理解。因此,近期我们对肿瘤进展和转移过程理解的增加,应为开发更有效的播散性癌症治疗方法提供重要线索。